| Year |
Citation |
Score |
| 2022 |
Kirkham B, Nash P, Reina D, Navarra S, Quebe-Fehling E, Gaillez C, Sastre C, Mease PJ. Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study. Clinical and Experimental Rheumatology. PMID 35916290 DOI: 10.55563/clinexprheumatol/vezf95 |
0.316 |
|
| 2022 |
Mease P, Kavanaugh A, Gladman D, FitzGerald O, Soriano ER, Nash P, Feng D, Lertratanakul A, Douglas K, Lippe R, Gossec L. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials. Rheumatology and Therapy. PMID 35606663 DOI: 10.1007/s40744-022-00449-6 |
0.314 |
|
| 2021 |
Nash P, Coates LC, Fleishaker D, Kivitz AJ, Mease PJ, Gladman DD, FitzGerald O, Wang C, Wu J, Hsu MA, Menon S, Fallon L, Kanik KS. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. The Lancet. Rheumatology. 3: e270-e283. PMID 38279411 DOI: 10.1016/S2665-9913(21)00010-2 |
0.31 |
|
| 2021 |
Tanaka Y, Matsubara T, Atsumi T, Amano K, Ishiguro N, Sugiyama E, Yamaoka K, Combe BG, Kivitz AJ, Bae SC, Keystone EC, Nash P, Matzkies F, Bartok B, Pechonkina A, et al. Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). Modern Rheumatology. PMID 34910188 DOI: 10.1093/mr/roab030 |
0.318 |
|
| 2021 |
Mease PJ, Gladman DD, Kavanaugh A, McGonagle D, Nash P, Guerette B, Nakasato P, Brunori M, Teng L, McInnes IB. Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. Rheumatology and Therapy. PMID 34536218 DOI: 10.1007/s40744-021-00369-x |
0.329 |
|
| 2021 |
Conaghan PG, Mysler E, Tanaka Y, Da Silva-Tillmann B, Shaw T, Liu J, Ferguson R, Enejosa JV, Cohen S, Nash P, Rigby W, Burmester G. Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. Drug Safety. PMID 33527177 DOI: 10.1007/s40264-020-01036-w |
0.333 |
|
| 2021 |
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, Kumar U, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy JS, Jahreis A, Genovese MC, ... ... Nash P, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the Rheumatic Diseases. PMID 33504485 DOI: 10.1136/annrheumdis-2020-219214 |
0.331 |
|
| 2021 |
Nash P, Richter S, Jardon S, Teng L, Walsh JA. AB0552 PROBABILITY OF ACHIEVING TREATMENT TARGETS WITH APREMILAST MONOTHERAPY IN BIOLOGIC-NAIVE PSORIATIC ARTHRITIS PATIENTS IN ACTIVE WITH MODERATE AND HIGH BASELINE DISEASE ACTIVITY Annals of the Rheumatic Diseases. 80: 1310-1311. DOI: 10.1136/ANNRHEUMDIS-2021-EULAR.2198 |
0.309 |
|
| 2020 |
Nash P, Mease PJ, Fleishaker D, Wu J, Coates LC, Behrens F, Gladman DD, Kivitz AJ, Wei JC, Shirinsky I, Menon S, Romero AB, Fallon L, Hsu MA, Wang C, et al. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance. The Lancet. Rheumatology. 3: e28-e39. PMID 38273637 DOI: 10.1016/S2665-9913(20)30339-8 |
0.315 |
|
| 2020 |
Smolen JS, Sebba A, Ruderman EM, Schulze-Koops H, Sapin C, Gellett AM, Sprabery AT, Li L, de la Torre I, Gallo G, Liu-Leage S, Pillai S, Reis P, Nash P. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. Rheumatology and Therapy. PMID 33200394 DOI: 10.1007/s40744-020-00250-3 |
0.33 |
|
| 2020 |
Walker D, Combe BG, Kivitiz AJ, Tanaka Y, van der Heijde D, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy JS, Mozaffarian N, Landewé RBM, Bae S, Keystone EC, ... Nash P, et al. P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results Rheumatology. 59. DOI: 10.1093/rheumatology/keaa111.205 |
0.309 |
|
| 2019 |
Strand V, van der Heijde D, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R, et al. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. Clinical and Experimental Rheumatology. PMID 31858963 |
0.323 |
|
| 2019 |
Bird P, Hall S, Nash P, Connell CA, Kwok K, Witcombe D, Thirunavukkarasu K. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. Rmd Open. 5: e000742. PMID 30886732 DOI: 10.1136/rmdopen-2018-000742 |
0.318 |
|
| 2019 |
van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Stanley Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R, et al. Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study. Arthritis & Rheumatology (Hoboken, N.J.). PMID 30666826 DOI: 10.1002/Art.40803 |
0.335 |
|
| 2019 |
Combe B, Tsai T, Odhav S, Huffstutter JE, Sprabery AT, Lin C, Park SY, Hufford M, Nash P. Sat0374 ixekizumab, with or without concomitant methotrexate, improves the signs and symptoms of psa for up to 52 weeks of treatment Annals of the Rheumatic Diseases. 78: 1270-1271. DOI: 10.1136/Annrheumdis-2019-Eular.1240 |
0.301 |
|
| 2018 |
Nash P, Behrens F, Orbai AM, Rathmann SS, Adams DH, Benichou O, Deodhar A. Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. Rmd Open. 4: e000692. PMID 30233812 DOI: 10.1136/rmdopen-2018-000692 |
0.307 |
|
| 2018 |
Hall S, Nash P, Rischmueller M, Bossingham D, Bird P, Cook N, Witcombe D, Soma K, Kwok K, Thirunavukkarasu K. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. Rheumatology and Therapy. PMID 29949132 DOI: 10.1007/s40744-018-0118-2 |
0.305 |
|
| 2018 |
Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW, Nasonov E, Durez P, Elegbe A, Wong R, et al. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. The Journal of Rheumatology. PMID 29657147 DOI: 10.3899/jrheum.170344 |
0.323 |
|
| 2018 |
Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gómez-Reino JJ, Aelion JA. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Annals of the Rheumatic Diseases. PMID 29343507 DOI: 10.1136/annrheumdis-2017-211568 |
0.316 |
|
| 2017 |
Charles-Schoeman C, van der Heijde D, Burmester GR, Nash P, Zerbini CAF, Connell CA, Fan H, Kwok K, Bananis E, Fleischmann R. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. The Journal of Rheumatology. PMID 29142036 DOI: 10.3899/Jrheum.170486 |
0.328 |
|
| 2017 |
Burmester GR, Kaeley GS, Kavanaugh AF, Gabay C, MacCarter DK, Nash P, Takeuchi T, Goss SL, Rodila R, Chen K, Kupper H, Kalabic J. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. Rmd Open. 3: e000465. PMID 28955494 DOI: 10.1136/rmdopen-2017-000465 |
0.318 |
|
| 2017 |
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Annals of the Rheumatic Diseases. PMID 28143815 DOI: 10.1136/Annrheumdis-2016-210457 |
0.3 |
|
| 2016 |
Genovese M, Pacheco Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos J, Box J, Legerton C, Nasonov E, Durez P, Elegbe A, Wong R, et al. FRI0227 Five-Year Safety and Efficacy of Subcutaneous Abatacept in Patients with Moderate To Severely Active RA and An Inadequate Response To MTX: Long-Term Extension of The Phase III, Double-Blind, Randomized Acquire Study: Annals of the Rheumatic Diseases. 75: 515.1-515. DOI: 10.1136/annrheumdis-2016-eular.1279 |
0.3 |
|
| 2015 |
Charles-Schoeman C, Burmester G, Nash P, Zerbini CA, Soma K, Kwok K, Hendrikx T, Bananis E, Fleischmann R. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases. PMID 26275429 DOI: 10.1136/Annrheumdis-2014-207178 |
0.326 |
|
| 2014 |
Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Box J, Legerton CW, Nasonov E, Durez P, Delaet I, Teng J, et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. The Journal of Rheumatology. 41: 629-39. PMID 24584926 DOI: 10.3899/jrheum.130112 |
0.327 |
|
| 2013 |
Emery P, Fleischmann RM, Doyle MK, Strusberg I, Durez P, Nash P, Amante E, Churchill M, Park W, Pons-Estel B, Xu W, Xu S, Wu Z, Hsia EC. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care & Research. 65: 1732-42. PMID 23861303 DOI: 10.1002/acr.22072 |
0.314 |
|
| 2013 |
Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 381: 918-29. PMID 23332236 DOI: 10.1016/S0140-6736(12)61811-X |
0.326 |
|
| 2009 |
Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis and Rheumatism. 60: 2272-83. PMID 19644849 DOI: 10.1002/art.24638 |
0.304 |
|
| 2008 |
Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis and Rheumatism. 58: 964-75. PMID 18383539 DOI: 10.1002/art.23383 |
0.342 |
|
| Show low-probability matches. |